Rayzon Solar Ranks Second in India's Module Shipments with 7.21% Share in FY26

1788494626 1259



CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *